Silence Therapeutics PLC - Asset Resilience Ratio
Silence Therapeutics PLC (SLN) has an Asset Resilience Ratio of 13.73% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Silence Therapeutics PLC's Asset Resilience Ratio has changed over time. Check SLN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Silence Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Silence Therapeutics PLC market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $20.16 Million | 13.73% |
| Total Liquid Assets | $20.16 Million | 13.73% |
Asset Resilience Insights
- Moderate Liquidity: Silence Therapeutics PLC has 13.73% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Silence Therapeutics PLC Industry Peers by Asset Resilience Ratio
Compare Silence Therapeutics PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Genfit S.A.
PA:GNFT |
Biotechnology | 64.01% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for Silence Therapeutics PLC (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Silence Therapeutics PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.83% | $26.00 Million | $202.63 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $119.45 Million | -- |
| 2022-12-31 | 15.19% | $16.33 Million | $107.50 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $96.19 Million | -- |
| 2020-12-31 | 11.63% | $10.00 Million | $85.97 Million | -31.78pp |
| 2019-12-31 | 43.41% | $20.00 Million | $46.08 Million | +30.44pp |
| 2018-12-31 | 12.97% | $5.04 Million | $38.88 Million | +12.39pp |
| 2017-12-31 | 0.58% | $319.00K | $55.01 Million | +0.57pp |
| 2016-12-31 | 0.01% | $3.00K | $55.79 Million | +0.00pp |
| 2015-12-31 | 0.00% | $2.00K | $61.55 Million | -16.79pp |
| 2014-12-31 | 16.79% | $5.00 Million | $29.77 Million | -0.27pp |
| 2013-12-31 | 17.06% | $5.00 Million | $29.30 Million | +17.05pp |
| 2012-12-31 | 0.01% | $2.00K | $17.07 Million | -- |
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more